New Migraine Treatments 2021



Article last updated on 4/1/2021

What is Migraine?

A migraine is a moderate to severe headache described as a beating pain on one side of the head. It can be accompanied by other symptoms, including sensitivity to sounds and light, or feeling sick (nausea, vomiting).

Although the exact causes of migraine attacks are still unknown, multiple studies have confirmed that release of calcitonin gene-related peptide (CGRP) is increased during acute migraine attacks.

The inhibition of CGRP and its receptor has proved effective in migraine pain relief, which suggests that it does contribute to the onset of a migraine.2


Is there a cure for Migraine?

A migraine cure is not yet available, so treatment aims to relieve symptoms.

Among the medication typically used are:

  1. Painkillers
  2. Triptans, to help reverse changes in the brain that may result in a migraine attack
  3. Antiemetics to reduce nausea and vomiting

What are the newest treatments and medications for Migraine?


Several medicines have been approved for treating migraines. Here are some chronic migraine treatments:


Vyepti (eptinezumab-jjmr)3,4

Vyepti (eptinezumab-jjmr) is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of adults.

On February 22, 2020 Vyepti (eptinezumab-jjmr) was approved for the preventive treatment of migraine in adults by The Food and Drug Administration (FDA), USA. It is the first FDA-approved intravenous (injection) treatment for migraine prevention.


Ubrelvy (ubrogepant)5,6

Ubrelvy (ubrogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the treatment of migraine headaches with or without aura. It will not prevent migraine headache.

On December 23, 2019 Ubrelvy (ubrogepant) was approved for the acute treatment of adults with migraine by The Food and Drug Administration (FDA), USA.

It is the first CGRP receptor antagonist that can be taken orally, when needed, for the treatment of acute migraine attacks.


Nurtec ODT (rimegepant)7,8,9,10

Nurtec ODT (rimegepant) is a medication used for the acute treatment of migraine with or without aura in adults.

On February 27, 2020 Nurtec ODT (rimegepant) was approved for the acute treatment of migraine in adults by The Food and Drug Administration (FDA), USA.

It is the first and only quick-dissolving tablet for migraine that can provide fast pain relief. Because it is an orally dissolvable tablet, rimegepant is taken up in the blood faster than a tablet, and will reach its maximum effect in 1.5 hrs.


Aimovig (erenumab)11,12,13,14,15,16

Aimovig (erenumab) is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the preventive treatment of migraine headaches.The medicine can be injected subcutaneously (under the skin) once per month.

Aimovig (erenumab) was approved for the treatment of patients with migraine by:

  • Food and Drug Administration (FDA), USA, on May 17, 2018
  • Therapeutic Goods Administration (TGA), Australia, July 2, 2018
  • Swissmedic, Switzerland, July 13, 2018
  • European Medical Agency (EMA), European Union, July 26, 2018, indicated for the treatment in adults with 4 or more migraine days per month
  • Health Canada, Canada, August 1, 2018, indicated for the treatment in adults with 4 or more migraine days per month
  • Medsafe, New Zealand, January 16, 2020

If you are trying to access a new migraine treatment that is approved outside of your country of residence, we might be able to help you access it with the help of your treating doctor. You can read more about the medicines we can help you access and their price below:




Why buy new Migraine medication with TheSocialMedwork?


TheSocialMedwork is registered in The Hague with the Dutch Ministry of Health (registration number 6730 BEM) as an independent medicines intermediary. We have helped patients from over 85 countries to access thousands of medicines including. With a prescription from your treating doctor, you can count on our expert team to safely and legally guide you to access a new migraine medication in 2020. If you or someone you know are looking to access a medicine that is not yet approved where they live, we can support you. Contact us for more information.


References:

  1. Nhs.uk
  2. Migraine.com
  3. Accessdata.fda.gov
  4. Investor.lundbeck.com
  5. Journals.lww.com
  6. Fda.gov
  7. Accessdata.fda.gov
  8. Biohavenpharma.com
  9. Americanmigrainefoundation.org
  10. Nejm.org
  11. Fda.gov
  12. Ebs.tga.gov.au
  13. Ema.europa.eu
  14. Swissmedic.ch/
  15. Medsafe.govt.nz

Disclaimer: This article is not meant to influence or impact the care provided by your treating physician. Please do not make changes to your treatment without first consulting your healthcare provider. This article is not intended to diagnose or treat illness or to influence treatment options. TheSocialMedwork is as diligent as possible in compiling and updating the information on this page. Howeve, TheSocialMedwork does not guarantee the correctness and completeness of the information provided on this page.